by Barry101 | Jun 14, 2021 | Press Release, Uncategorized
The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade InhibitorsOCALA, Fla., June 14, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a...
by Barry101 | May 27, 2021 | Press Release, Uncategorized
Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positiveOCALA, Fla., May 27, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a...
by Barry101 | May 26, 2021 | Press Release, Uncategorized
OCALA, Fla., May 26, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting...
by Barry101 | May 18, 2021 | Press Release, Uncategorized
OCALA, Fla., May 18, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to...
by Barry101 | May 18, 2021 | Uncategorized
OCALA, Fla., May 18, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to...
